期刊
JOURNAL OF THE NEUROLOGICAL SCIENCES
卷 211, 期 1-2, 页码 81-84出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/S0022-510X(03)00060-1
关键词
progressive multiple sclerosis; efficacy; triamcinolone acetonide; intrathecal
Available immunomodulatory and conventional steroid treatment options for patients with progressive multiple sclerosis (MS) only provide limited symptomatic benefit. We performed an open trial on the short-term and long-term efficacy and safety of repeated intrathecal application of the sustained release steroid triamcinolone acetonide (TCA) in 36 progressive MS patients. Six TCA administrations, performed every third day, reduced the EDSS score (initial: 5.6 +/- 0.93 [mean +/- S.D.]; end: 4.9 +/- 1.0; p < 0.001) and increased the walking distance (WD) (initial: 294 +/- 314 m; end: 604 +/- 540 in; p < 0.001). Twenty MS patients continued intrathecal TCA treatment with one TCA injection performed with a variable frequency ranging from 6 to 12 weeks. Both EDSS and walking distance remained stable in these patients until the end of the follow-up investigation period. No serious side effects occurred. We conclude that repeated intrathecal TCA injection provides substantial benefit for progressive MS patients with predominantly spinal symptoms. (C) 2003 Elsevier Science B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据